Genetic Polymorphisms Can Predict the Efficacy and Toxicity of Celecoxib in Patients With Adenomatous Polyps

被引：0
|
作者：
Kraus, Sarah
Hummler, Simone
Toriola, Adetunji T.
Poole, Elizabeth M.
Kotzmann, Jana
Makar, Karen M.
Kazanov, Diana
Galazan, Lior
Naumov, Inna
Duggan, David
Ulrich, Cornelia M.
Arber, Nadir
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S518 / S518
页数：1
相关论文
共 50 条
  • [1] Can genetic factors be useful to predict cardiovascular toxicity in patients with oncohematological diseases?
    Kopeva, Kristina
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2025,
  • [2] Genetic screening can predict chemo toxicity and benefits
    Reactions Weekly, 2005, 1076 (1) : 4 - 4
  • [3] Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
    A V Khrunin
    A Moisseev
    V Gorbunova
    S Limborska
    The Pharmacogenomics Journal, 2010, 10 : 54 - 61
  • [4] Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
    Khrunin, A. V.
    Moisseev, A.
    Gorbunova, V.
    Limborska, S.
    PHARMACOGENOMICS JOURNAL, 2010, 10 (01): : 54 - 61
  • [5] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
    Lamas, M. J.
    Duran, G.
    Balboa, E.
    Bernardez, B.
    Candamio, S.
    Vidal, Y.
    Mosquera, A.
    Giraldez, J. M.
    Lopez, R.
    Carracedo, A.
    Barros, F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1591 - 1599
  • [6] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
    M. J. Lamas
    G. Duran
    E. Balboa
    B. Bernardez
    S. Candamio
    Y. Vidal
    A. Mosquera
    J. M. Giraldez
    R. Lopez
    A. Carracedo
    F. Barros
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1591 - 1599
  • [7] Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial
    Bjorn WH van Heumen
    Hennie MJ Roelofs
    M Elisa Vink-Börger
    Evelien Dekker
    Elisabeth MH Mathus-Vliegen
    Jan Dees
    Jan J Koornstra
    Alexandra MJ Langers
    Iris D Nagtegaal
    Ellen Kampman
    Wilbert HM Peters
    Fokko M Nagengast,
    Orphanet Journal of Rare Diseases, 8
  • [8] Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
    Winther, Stine Braendegaard
    Jorgensen, Trine Lembrecht
    Pfeiffer, Per
    Qvortrup, Camilla
    ESMO OPEN, 2016, 1 (03)
  • [9] Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial
    van Heumen, Bjorn W. H.
    Roelofs, Hennie M. J.
    Vink-Borger, M. Elisa
    Dekker, Evelien
    Mathus-Vliegen, Elisabeth M. H.
    Dees, Jan
    Koornstra, Jan J.
    Langers, Alexandra M. J.
    Nagtegaal, Iris D.
    Kampman, Ellen
    Peters, Wilbert H. M.
    Nagengast, Fokko M.
    ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [10] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas, M. J.
    Duran, G.
    Balboa, E.
    Candamio, S.
    Bernardez, B.
    Carracedo, A.
    Lopez, R.
    Barros, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345